中国实用内科杂志

中国实用内科杂志 ›› 2012, Vol. 32 ›› Issue (12): 900-902.

• 专题笔谈 • 上一篇    下一篇

合理应用人促红细胞生成素治疗肾性贫血

付平，陈肖蕾   

  1. 作者单位：四川大学华西医院肾脏内科，成都 610041
  • 出版日期:2012-12-01 发布日期:2012-11-22

Appropriate management of anemia with human erythropoietin in chronic kidney disease.

FU Ping，CHEN Xiao-lei.　　　　　　　　　　　　　　　　　　　   

  1. Department of Nephrology，West China Hospital of Sichuan University，Chengdu 610041， China
  • Online:2012-12-01 Published:2012-11-22

PDF

摘要：

基因重组人促红细胞生成素(rHuEPO)是治疗肾性贫血的主要药物，2012年改善全球肾脏病预后组织(KDIGO)贫血治疗指南根据最新的研究结果对EPO在慢性肾脏病的应用规范提出了建议。本文将从血红蛋白目标值、EPO治疗的启动时机、给药方案、EPO的反应性等方面进行讨论，探寻更加合理的EPO应用策略。在纠正贫血的过程中，应兼顾EPO治疗的获益和风险。

关键词: 促红细胞生成素, 慢性肾脏病, 贫血, EPO低反应性

Abstract:

Human erythropoietin has been the mainstay treatment of renal anemia.The 2012 guideline for treatment of anemia，drafted by Kidney Disease: Improving Global Outcomes (KDIGO)，issued the recommendations for clinical application of human erythropoietin in patients with chronic kidney disease based on the latest literature report.This review was designed to delineate the target concentration of hemoglobin，initiation of erythropoietin therapy，protocols for administration and the efficacy，thus optimizing the use of erythropoietin.The merits and potential risks of erythropoietin should be carefully weighed in the treatment of anemia.

Key words: erythropoietin, chronic kidney disease, anemia, erythropoietin hyporesponsiveness

中图分类号: